Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

Inclusion Criteria: * Subjects must have a clinical diagnosis of moderate to severe melasma * Subjects willing to undergo biopsy four times throughout the study, two biopsies at baseline (one in a melasma involved area and one in a non-involved area). The third and fourth biopsies will be performed at 3 months and 6 months, respectively; in order to avoid variability in histopathological findings, * Subjects must have substantial melasma involvement of the cheeks and be willing to have the same general site biopsied at the baseline, month 3 and month 6 visits. Exclusion Criteria: * Subjects with diagnosis of dermal melasma * Subjects who foresee intensive UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.) * Subjects who have used retinoids, steroids, and/or skin lightening products 4 weeks prior to study entry * Subjects who show signs of Poikiloderma of Civatte (mandibular hyperpigmentation) * Subjects with a history of hypertrophic scarring or a history of keloids * Subjects who are unable to avoid the use of a class 1 steroid during their participation in the study